



PROPOSED DOCUMENT

Global Harmonization Task Force

Title: Definition and Classification of Field Corrective Actions, including Field Safety Corrective Actions, Recalls and Non Safety related Field Corrective Actions.

Authoring Group: Study Group 2

Date: October 6, 2011

Table of Contents

Preface	3
Preamble	4
1 Introduction	4
2 Scope	5
3 References	5
4 Definitions	5
5 Examples of Field Safety Corrective Action (FSCA) Types	6
6 Examples of Non Safety related Field Corrective Action types	9
7 Classification of FCAs	10
8 Examples of classification of FCAs	11

Preface

The document herein was produced by the Global Harmonization Task Force (GHTF), a voluntary group of representatives from national medical device regulatory agencies (RAs) and the regulated medical device industry (Industry). The document is intended to provide *non-binding* guidance to RAs for use in the regulation of medical devices, and has been subject to consultation throughout its development.

There are no restrictions on distribution or use of this document; however, incorporation of this document, in part or in whole, into any other document, or its translation into languages other than English, does not convey or represent an endorsement of any kind by the Global Harmonization Task Force or their associated member organizations.

Preamble

The proposed SG2 document provides guidance for actions related to Field Corrective Actions (FCAs), i.e. Field Safety Corrective Actions (FSCAs) as defined in N57 and Non Safety related Field Corrective Actions (NFSCAs).

The objective of the document is two fold:

- (1) to define in view of clarification and harmonization the different types of field safety corrective actions and non-safety related field corrective actions taken on a marketed product and
- (2) to classify field corrective actions according to the level of risks posed to patients, users and others.

The document structure reflects this dual purpose:

- the first sections (4, 5 & 6) provide definitions and examples for the different types of FSCAs and NFSCAs.
- the last sections (7 & 8) define the different risk classes of FCAs and give examples for each of the risk class.

Examples for each risk class are taken from examples in sections 5 and 6.

1 Introduction

This document was developed by Study Group 2 of the GHTF to provide guidance and information to National Competent Authorities (NCAs) and the medical device industry (Industry) on definitions, terms and classification of field corrective actions (FCAs) taken on marketed medical devices.

Harmonization will improve communication among NCAs, and NCAs and Industry, as well as increases clarity for users and the general public that may be affected by these actions.

Currently, the term “recall” is not harmonized. In some jurisdictions the term “recall” is strictly applied to actions that include the removal of medical devices from the market. In others, the term is applied more broadly and covers other types of field corrective actions.

This document defines “Field Corrective Actions” (FCAs) which include “Field Safety Corrective Actions” (FSCAs) as defined in N57 and “Non Safety related Field Corrective Actions” to address field corrective actions taken by the manufacturer with respect to medical devices. These actions are classified based on the type and extent of corrective action and the level of risk posed to patients, users or others affected by the device usage

The primary reasons for a risk based classification are to identify the level of risk posed to patients, users and others, for manufacturers to develop a comprehensive FCA strategy, including planning for communication, action and follow up and for NCAs to monitor the completion of the FCA in accordance with the identified risks and review any additional action that may be required.

2 Scope

The document provides guidance for actions related to FSCAs as defined in N57 and Non Safety related Field Corrective Actions.

The regulatory classification of actions sets out the level of risk posed to patients, users and others by the problem being addressed by the FCAs.

3 References

GHTF SG2 N57:2006	Content of Field Safety Notices.
ISO 14971:2009	Medical Device Risk Management .
GHTF SG2 N54:2006	Global Guidance for Adverse Event Reporting for Medical Devices.

4 Definitions

Field Corrective Action (FCA)

A Field Corrective Action is an action taken on a marketed product which can be a Field Safety Corrective Action (FSCA) or a Non Safety related Field Corrective Actions.

Field Safety Corrective Action (FSCA)

A Field Safety Corrective Action is an action taken by a manufacturer to reduce a risk of death or serious deterioration in the state of health associated with the use of a medical device. (Source: GHTF SG2 N57:2006, section 3).

The five types of FSCA are listed below. Related examples are provided in section 5.

FSCA Type 1 / Device Removal (“Device Recall”)

The permanent removal from the market and / or destruction of devices, when the device has or may have a safety problem.

FSCA Type 2 / Device Modification:

The repair, modification, or adjustment of the device or the label and/or instructions for use when the device has or could cause a safety problem. The corrective action may take place at the users' or the manufacturer's premises or any other agreed upon location.

FSCA Type 3/ Implant Alert:

The issuing of precautionary information about a device where the affected devices are already implanted.

FSCA Type 4/ Device Precaution:

The issuing of information and precautionary measures about adverse events with a medical device where neither the root cause nor their resolution has been established but it is likely that follow up action will be necessary.

FSCA Type 5/ User Warning:

The issuing of information which would warn of a potential patient safety risk that may arise from procedural or medical device use.

Non Safety related Field Corrective Action

Any field corrective action taken by the manufacturer for reasons other than to reduce a risk of death or serious deterioration in the state of health associated with the use of the medical device.

The three types of non safety related field corrective action are listed below. Related examples are presented in section 6.

Non safety related field corrective action Type 1/ Device Withdrawal:

The removal of a product from supply and use when the medical device does not pose a safety problem.

Non safety related field corrective action Type 2/ Device Enhancement:

The enhancement or upgrade that improves the features and performance of a medical device that is not related to safety reasons.

Non safety related field corrective action Type 3/ Stock Recovery:

The correction or removal from supply of a device that has not been marketed or that has not left the direct control of the manufacturer.

5 Examples of Field Safety Corrective Action (FSCA) Types

FSCA Type 1- Device Removal (“Device recall”)

The permanent removal from the market and / or destruction of devices, when the device has or may have a safety problem.

Example 1: Following a report concerning a nurse being contaminated by a chemotherapy agent, an investigation by the manufacturer into adverse event reports about the splitting of the barrel of syringes used to inject cytotoxic chemotherapy drugs determines that the root cause was a manufacturing error and that batches manufactured between certain dates are affected. To prevent potential unintended exposure to chemotherapy or other harm caused by the use of a defective syringe, the manufacturer contacts all distributors and users who received syringes from the affected batches, requesting their return for disposal by the manufacturer or documentation of disposal by the distributors or users. Batches outside of the range identified are not affected and can be used or supplied. **The permanent removal or destruction of the potentially faulty syringes from the market for safety reasons makes this action an FSCA Type 1.**

Example 2: The manufacturer has received reports about catheter balloons bursting during procedures to remove blood clots from patients’ arteries. An investigation by the manufacturer reveals that the material and design used for these balloon catheters is the

same as for those used to inflate coronary artery stents and that the medical device may not be appropriate for use in removing blood clots. The manufacturer has decided that all balloon catheters intended to be used for removal of blood clots and have this design and material must be returned to them even though this same design and material is considered to be safe when used for coronary arteries stenting. **The permanent removal of this medical device model for safety reasons makes this action a FSCA Type 1.**

Example 3: The manufacturer of an in-vitro testing device receives reports that the software error results in false positives to the test. Based on these inaccurate test results, the patients received unnecessary treatment associated with significant toxicity. Reports were also received of false negative test results, which delayed treatment until the patient became symptomatic. The manufacturer determined that a software modification will not resolve the inaccurate test results, so requested all laboratories using the device to return all units. **The permanent removal or destruction of a device for safety reasons makes this action an FSCA Type 1.**

FSCA Type 2 - Device Modification

The repair, modification, or adjustment of the device or the label and/or instructions for use when the device has or could cause a safety problem. The corrective action may take place at the users' or the manufacturer's premises or any other agreed upon location.

Example 1: Patient was misdiagnosed because images from a CT scan were mislabeled. During the investigation of the event, the manufacturer discovered that the cause was user error that could be mitigated by a software correction. A “software patch” was delivered to all users of the system with instructions for imaging technicians at the radiology centers on how to install and validate the “software patch” – users of the system were also given the option for a manufacturer’s service agent to install the service pack. **The act of providing a software patch or service upgrade for safety reasons makes this an FSCA Type 2.**

Example 2: A number of adverse events with a negative pressure wound therapy device have been reported to the manufacturer. The instructions for use were missing or did not include warnings against use of this device on patients with particular medical conditions. The manufacturer has added the additional warnings to the instructions for use and sent out a new version to all users to replace the original instructions for use. **The act of providing additions to or replacement versions of instructions for use to for safety reasons, even if replaced by the user, makes this an FSCA Type 2.**

Example 3: A manufacturer received multiple reports of inadvertent activation of an insulin pump during patient movement which could result in inappropriate drug delivery. The manufacturer sent all users a protecting ring to be placed around the device activation switch, to prevent accidental activation. **Medical device replacement or changes which offer improvements to performance for safety reasons, even if replaced by the user, makes this an FSCA Type 2.**

FSCA Type 3 - Implant Alert

The issuing of precautionary information about a device where the affected devices are already implanted.

Example 1: A manufacturer discovers that certain models of a specific pacemaker may reach their end of life prematurely. The investigation finds the cause to be related to the reliability of an electrical component. The manufacturer issues an advisory to implanting surgeons and cardiologists to counsel and to follow those implanted patients at more regular intervals and only replace devices as appropriate. **The act of communicating a problem about an implantable device and providing information about patient follow up or elective device replacement makes this an FSCA Type 3.**

Example 2: An increasing number of adverse events involving surgical mesh implanted into the bladder for problems with urinary incontinence have been received by the manufacturer. The meshes have eroded into surrounding tissues and the patients continue to experience severe pain and incontinence. Due to the extent of the internal damage, it is not known if the mesh can be safely removed without further serious injury. The manufacturer issues a labeling update, notifying physicians about the situation and advising them to communicate to the patient prior to implantation regarding the increase in known adverse events and the need to monitor patients who have the mesh already implanted. **The act of communicating to physicians about potential problems with implants makes this an FSCA Type 3.**

FSCA Type 4 - Device Precaution

The issuing of information and precautionary measures about adverse events with a medical device where neither the root cause nor their resolution has been established but it is likely that follow up action will be necessary.

Example 1: The manufacturer has received reports about the failure of a particular model of anesthetic machine when operated in a certain mode. The manufacturer is still investigating this particular problem and its potential corrective actions. There are few alternative methods of delivering anesthetic available. The manufacturer decides to inform users of this problem and advise them that this mode should not be used until they have determined the solution to the problem. Once a cause and corrective solution has been found, further information will be distributed to users. Based on the progress in the investigation, the manufacturer may take additional FSCA. **Notifying users of a problem without a known resolution while continuing to investigate makes this an FSCA Type 4.**

FSCA Type 5 - User Warning

The issuing of information which would warn of a potential patient safety risk that may arise from procedural or medical device use.

Example 1: A number of adverse events with a thermal ligature sealer have been reported to the manufacturer. The investigation revealed that surgical drapes and/or patients have been burned. Further information revealed the user had placed the ligature sealer down on

the drapes during the procedure. Placing the ligature sealer on the drapes is contrary to the instructions for use. A notice was sent to all known users of ligature sealers stressing the need to place the sealer in a proper holder instead of on the surgical drapes because of the potential for burns. **The act of sending out a user warning reminder to prevent a safety issue, even though there had been no medical device fault, makes this an FSCA Type 5.**

Example 2: The manufacturer has been notified of instances where an In-Vitro Diagnostic Device (IVDD) kit for HIV has been used for diagnosis instead of its intended purpose of screening. The manufacturer issued a reminder notice to pathology laboratories and physicians that the IVDD kit was not specifically developed for a definitive diagnosis of HIV. The instructions for use state that this IVDD kit is for screening purposes only and that it should not be used as a confirmatory test. Patients may be incorrectly diagnosed and treated with drugs that have serious side effects. **Notifying the user of the medical device's limitations and usage to avoid an incorrect diagnosis makes this an FSCA Type 5.**

6 Examples of Non Safety related Field Corrective Action types

Non safety related field corrective action Type 1- Withdrawal

The removal of a medical device from supply and use when the medical device does not pose a safety issue.

Example 1: A manufacturer terminates the sale and distribution of a prepared plated media (PPM) line that tests for methicillin resistant *staphylococcus aureus* because they recently received approval to market an automated rapid instrument system which will replace the current PPM line. This line will be exchanged or replaced by a newer version. **Because this medical device change does not raise safety issues, the event is a Non Safety related Field Corrective Action Type 1.**

Example 2: A manufacturer decides to remove a range of wound care medical devices that are not as widely used as a similar medical device due to a business and marketing decision. Safety and liability were not factors in the decision. The medical devices are removed from the shelves and may or may not be replaced with other similar medical devices. **Medical device removal due solely to a business decision is a Non Safety related Field Corrective Action Type 1.**

Example 3: A manufacturer decides to remove a batch of thermometer probe covers from customer's shelves because of complaints that the covers are sticking together preventing their use. The covers are removed and replaced with covers from a different batch. **Medical device removed due to a quality complaint, that would not pose a safety problem is a Non Safety related Field Corrective Action Type 1.**

Non safety related field corrective action Type 2 - Device Enhancement

The enhancement or upgrade that improves the features and performance of a medical device that is not related to safety reasons.

Example 1: The manufacturer of a CT scanner has developed a software add-on that will enable the user to perform additional functions. The manufacturer sends the software add-on with updated instructions for use to the healthcare facility for their technicians to load onto the scanner or offers to send one of their technicians to the facility to load the software. **Enhancements to the functionality of medical devices where there are no improvements indicated by safety issues are Non Safety related Field Corrective Action Type 2.**

Example 2: The manufacturer discontinues an In-Vitro Diagnostic Device (IVDD) line and replaces it with one in which controls are now supplied in a single-use only vial, offering better stability and better Quality Control. The old IVDD will still be supplied until stock depletion. **Replacement or changes to medical devices which offer improvements to performance are Non Safety related Field Corrective Action Type 2.**

Non safety related field corrective action Type 3 - Stock Recovery

The correction or removal from supply of a device that has not been marketed or that has not left the direct control of the manufacturer.

Example 1: A manufacturer discovers that due to a manufacturing error on one lot, only one of the two tools is included in a surgical kit. The manufacturer adds the missing tool in the instrument trays within their own manufacturing and distribution location sites before the device is placed on the market. **Error corrections for medical devices that have not left the manufacturer's control are Non Safety related Field Corrective Action Type 3.**

Example 2: The manufacturer has identified that incorrect power is labeled on a lot of Intraocular Lenses (IOLs). The lot is contained within the company manufacturing and distribution sites. The entire lot is quarantined by the manufacturer prior to release into the market. **Error corrections that have not left the manufacturer's control are Non Safety related Field Corrective Action Type 3.**

7 Classification of FCAs

Classifications are proposed by the manufacturer identifying the level of risk posed to patients, users and others if the device is continued to be used. Classification is divided into three classes which are listed below. Related examples are presented in section 8.

FCA Class 1

A field corrective action taken by the manufacturer when death or serious deterioration in the state of health of a patient, user or other person has happened or there is a reasonable probability¹ that exposure to or use of the medical device(s) can lead to death or serious deterioration² in the state of health of a patient, user or other person.

FCA Class 2

A field corrective action taken by the manufacturer when there is a reasonable probability that the exposure or use of the medical device(s) has or can lead to temporary illness, injury, mistreatment or deterioration of the state of health of a patient, user or other person.

FCA Class 3

A field corrective action taken by the manufacturer when there is a reasonable probability that the exposure or use of the medical device will not lead to temporary illness, injury, mistreatment or deterioration of the state of health of a patient, user or other person.

8 Examples of classification of FCAs

The initial classification of notifiable FCAs³ is proposed by the manufacturer based on information available which is accepted by the NCA. Should new information become available, the classification may be adjusted.

When an FCA includes multiple corrective actions with different classification of risks, the actions associated with the highest level of risk takes precedence.

Classification examples are taken from FCA examples in sections 5 and 6.

FCA Class 1

A field corrective action taken by the manufacturer when death or serious deterioration in the state of health of a patient, user or other person has happened or there is a reasonable probability¹ that exposure to or use of the medical device(s) can lead to death or serious deterioration² in the state of health of a patient, user or other person.

Example 1 (Implant Alert): An increasing number of adverse events involving surgical mesh implanted into the bladder for problems with urinary incontinence have been

¹ For the purpose of this document, a reasonable probability is the likelihood that an event could recur based on a risk analysis of all available information

² As defined in GHTF SG2 N54:2006, section 3.3.2

³ Notifiable actions may vary between jurisdictions

received by the manufacturer. The meshes have eroded into surrounding tissues and the patients continue to experience severe pain and incontinence. Due to the extent of the internal damage, it is not known if the mesh can be safely removed without further serious injury. The manufacturer issues a labeling update, notifying physicians about the situation and advising them to communicate to the patient prior to implantation regarding the increase in known adverse events and the need to monitor patients who have the mesh already implanted.

Rationale: Due to the inability to remove the surgical mesh, patients have suffered or can suffer a serious deterioration in their state of health, making this a Class 1 FCA.

Example 2 (Device Modification): A manufacturer received multiple reports of inadvertent activation of an insulin pump during patient movement which could result in inappropriate drug delivery. The manufacturer sent all users a protecting ring to be placed around the device activation switch, to prevent accidental activation.

Rationale: Inappropriate drug delivery of insulin to patients can lead to death or serious deterioration of health of the patient making this a Class 1 FCA.

FCA Class 2:

A field corrective action taken by the manufacturer when there is a reasonable probability that the exposure or use of the medical device(s) has or can lead to temporary illness, injury, mistreatment or deterioration of the state of health of a patient, user or other person.

Example 1 (User Warning): A number of adverse events with a thermal ligature sealer have been reported to the manufacturer. The investigation revealed that surgical drapes and/or patients have been burned. Further information revealed the user had placed the ligature sealer down on the drapes during the procedure. Placing the ligature sealer on the drapes is contrary to the instructions for use. A notice was sent to all known users of ligature sealers stressing the need to place the sealer in a proper holder instead of on the surgical drapes because of the potential for burns.

Rationale: Due to the instructions not being followed, there is possibility of temporary injury to patients or users, making this a Class 2 FCA.

Example 2 (Device Removal): Following a report concerning a nurse being contaminated by a chemotherapy agent, an investigation by the manufacturer into adverse event reports about the splitting of the barrel of syringes used to inject cytotoxic chemotherapy drugs determines that the root cause was a manufacturing error and that batches manufactured between certain dates are affected. To prevent potential unintended exposure to chemotherapy or other harm caused by the use of a defective syringe, the manufacturer contacts all distributors and users who received syringes from the affected batches, requesting their return for disposal by the manufacturer or documentation of disposal by the distributors or users. Batches outside of the range identified are not affected and can be used or supplied.

Rationale: The unintended exposure to cytotoxic drugs can lead to temporary injury or deterioration in state of health of patient or user making this a Class 2 FCA.

FCA Class 3:

A field corrective action taken by the manufacturer when there is a reasonable probability that the exposure or use of the medical device will not lead to temporary illness, injury, mistreatment or deterioration of the state of health of a patient, user or other person.

Example 1 (Device Enhancement): The manufacturer discontinues an In-Vitro Diagnostic Device (IVDD) line and replaces it with one in which controls are now supplied in a single-use only vial, offering better stability and better Quality Control. The old IVDD will still be supplied until stock depletion,

Rationale: It is unlikely that injury, illness or deterioration in the patient's health will occur as a result of continued use of the old IVDD making this a Class 3 FCA.

Example 2 (Stock Recovery): A manufacturer discovers that due to a manufacturing error on one lot, only one of the two tools is included in a surgical kit. The manufacturer adds the missing tool in the instrument trays within their own manufacturing and distribution location sites before the device is placed on the market.

Rationale: This is unlikely to cause any injury or deterioration in the state of health of the patient as the correction is being taken before the device is used making this a Class 3 FCA.